Cumberland Partners Ltd Has $12.29 Million Position in Johnson & Johnson $JNJ
Cumberland Partners Ltd reduced its stake in Johnson & Johnson (NYSE:JNJ) by 12.4% in the fourth quarter, selling 8,440 shares but still holding 59,375 shares valued at $12.29 million. Other institutional investors also adjusted their holdings in JNJ. Johnson & Johnson reported strong Q1 earnings, beating analyst expectations, raising full-year guidance, and increasing its quarterly dividend to $1.34 per share, contributing to a "Moderate Buy" consensus rating among analysts with an average price target of $253.04.
Americana Partners LLC Grows Stock Position in Johnson & Johnson $JNJ
Americana Partners LLC increased its stake in Johnson & Johnson (NYSE:JNJ) by 6.3% in the fourth quarter, bringing its total holdings to 197,070 shares valued at approximately $40.8 million. Wall Street analysts maintain a "Moderate Buy" rating for JNJ with an average target price of $253.04. Johnson & Johnson recently reported strong quarterly earnings, exceeding EPS and revenue estimates, and raised its quarterly dividend to $1.34 per share, offering a 2.3% yield.
Pfizer class action alleges website tracked users despite cookie opt-outs
A new class action lawsuit has been filed against Pfizer, alleging the company illegally tracked users' website activity and shared their data with third parties like Google, even after users declined cookies and tracking tools on its website. The plaintiff claims Pfizer's website deployed tracking tools immediately upon visit, prior to users interacting with privacy settings, and continued data sharing despite explicit opt-outs. This lawsuit accuses Pfizer of violating federal and California privacy laws.
Merck & Co., Inc. stock (US58933Y1055): Key cancer drug data and dividend profile in focus
Merck & Co., Inc. is gaining attention for its strong oncology data, particularly concerning its blockbuster cancer therapy Keytruda, and its consistent dividend payouts. The article details Merck's business model, emphasizing its focus on R&D, product diversification, and robust financial profile, while also noting the risks associated with its reliance on Keytruda. Key updates on its pipeline and significance for US investors are also highlighted.
Cantor Fitzgerald reiterates Overweight on ORIC Pharmaceuticals stock By Investing.com
Cantor Fitzgerald has reiterated an Overweight rating on ORIC Pharmaceuticals (NASDAQ:ORIC), despite the stock appearing overvalued according to InvestingPro analysis, with analysts' price targets ranging from $15 to $25. Key opinion leaders see a 60% probability of success for Pfizer’s mevrometostat in the Phase 3 MEVPRO-1 trial, which holds implications for ORIC, and ORIC itself holds more cash than debt, offering financial flexibility. Recent developments for ORIC include a Goldman Sachs upgrade to Buy, promising clinical data for rinzimetostat, but also trial results for rinzimetostat that matched but did not exceed a competing therapy.
Pfizer: Reduced TrumpRx/Patent Risks Meet Accretive M&A Efforts - Reiterate Buy (NYSE:PFE)
Pfizer (PFE) remains a "Great Buy" due to its aggressive M&A and R&D efforts, with newly launched products contributing significantly to revenue growth. The delayed generic entry for Vyndamax to mid-2031 further mitigates patent expiration risks, supporting long-term revenue guidance. Despite anticipated near-term performance lumpiness, cost-saving initiatives, strong interest coverage, and sustainable dividends, coupled with discounted valuations, make PFE an attractive investment with high dividend yields compared to peers.
TG Therapeutics Raises 2026 Outlook As Briumvi Drives Concentrated Growth
TG Therapeutics has raised its revenue guidance for 2026, primarily due to the strong performance of its multiple sclerosis drug, Briumvi. The company is actively pursuing new autoimmune indications for Briumvi, indicating a strategic focus on expanding its core product's market reach. While this approach concentrates both opportunity and risk, investors are showing confidence, with the stock up 29% in the past three months.
Ascentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026
Ascentage Pharma announced the presentation of clinical data from six of its studies at the 2026 ASCO Annual Meeting, with three selected for rapid oral presentations and three for poster presentations. The data pertains to lead drug candidates olverembatinib, lisaftoclax, and alrizomadlin, demonstrating their efficacy and safety in treating various cancers including CML, Ph+ BCP-ALL, rhabdomyosarcoma, and SDH-deficient tumors. These presentations highlight the company's progress in developing novel therapies for unmet medical needs in oncology.
Lung cancer trial: silevertinib shows 86% brain response, 60% tumor response
Black Diamond Therapeutics (Nasdaq: BDTX) announced positive Phase 2 results for silevertinib in frontline non-small cell lung cancer (NSCLC) patients with EGFR non-classical mutations. The drug demonstrated an 86% brain response rate and a 60% overall tumor response rate, along with a median progression-free survival of 15.2 months. These findings support a 150 mg once-daily dose for future pivotal development, and the company plans to discuss its pivotal development plan with the FDA later this year.
FDA plans rare advisory hearing to debate Moderna’s flu shot
The FDA is planning a rare advisory hearing next month to review Moderna's experimental mRNA flu shot, signaling a potential increase in transparency after recent controversies. This follows the agency's initial refusal and subsequent reversal to review Moderna's application, which had surprised many. The hearing will allow external experts to provide recommendations, a practice that was less common during the previous administration.
Early cancer trial sees tumor shrinkage in 13 of 19 on Olema drug
Olema Oncology reported encouraging initial Phase 1 data for its oral KAT6 inhibitor, OP-3136, in patients with advanced solid tumors. The drug demonstrated acceptable tolerability with no dose-limiting toxicities and showed promising anti-tumor activity, including tumor shrinkage in 13 of 19 evaluable patients and three partial responses. These findings support further development of OP-3136 as monotherapy and in combination with other treatments.
Pfizer Inc. Trade Ideas — BX:PFEUSD
This article compiles various trade ideas and analyses for Pfizer (PFE) stock, highlighting both bullish and bearish perspectives. A significant focus is on Pfizer's potential in the GLP-1 market with its oral weight-loss drugs, danuglipron and lotiglipron, which some analysts believe could be a game-changer despite the company's recent stock decline and patent expiry challenges. Other analyses discuss technical indicators, support/resistance levels, and fundamental concerns such as patent cliffs and declining COVID-19 related sales, ultimately presenting a mixed outlook for investors.
Amgen CFO Change Puts Focus On Debt, Growth And Capital Discipline
Amgen has announced that its long-serving CFO, Peter Griffith, will retire, with Thomas Dittrich appointed as his successor, effective September 1, 2026. This transition is significant for investors, as the new CFO's approach to capital allocation and debt management will be crucial, especially given Amgen's current debt levels and ongoing regulatory scrutiny for certain products. The extended handover period until January 2027 suggests a smooth transition, but investors will be closely watching for shifts in the company's financial discipline and communication regarding growth and spending.
Building an AI-Fluent Organization: How Pfizer is helping colleagues understand, embrace, and apply AI
Pfizer is actively working to become an "AI-Fluent Organization" by investing in AI literacy for its employees, driven by CEO Albert Bourla's belief that organizational ability, not technology, is the main barrier to unlocking AI's potential. The company's strategy involves building awareness, curiosity, and comfort with AI through programs like the Pfizer AI Academy and an enterprise-wide AI Fluency Development Goal, ensuring all colleagues can leverage AI to create breakthroughs for patients.
Merck & Co., Inc. stock (US58933Y1055): cancer franchise drives outlook after latest Keytruda data
Merck & Co., Inc. has highlighted new clinical data for its cancer drug Keytruda and provided updates on its late-stage pipeline, reinforcing growth expectations despite future patent expiries. The company positions itself as a leading oncology and vaccines player, with Keytruda remaining its dominant revenue driver and vaccines contributing stable growth. Merck's strategy involves sustained R&D investment, strategic collaborations, and diversification across therapeutic areas to mitigate competitive and regulatory pressures.
Building an AI-Literate Organization: How Pfizer is helping colleagues understand, embrace, and apply AI
Pfizer is actively working to make its organization AI-literate, recognizing that the biggest barrier to unlocking AI's potential is fear of the unknown. The company is investing in AI fluency for all colleagues through foundational training programs and the Pfizer AI Academy, aiming to build awareness, curiosity, and comfort with the technology. This initiative is supported by an enterprise-wide development goal to cultivate baseline AI capabilities across all levels and functions, empowering employees to leverage AI for breakthroughs in patient care.
Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Report 2026 Featuring Major Players Novo Nordisk A/S, Eli Lilly and Company, and Pfizer - Global Forecast to 2030 and 2035
The Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market is projected to grow from $15.5 billion in 2025 to $18.02 billion in 2026, reaching $32.87 billion by 2030, driven by rising obesity rates, new drug approvals like Eli Lilly's Zepbound, and increased insurance coverage. Key players include Novo Nordisk A/S, Eli Lilly and Company, and Pfizer Inc. While tariffs pose cost challenges, they also encourage domestic production, contributing to the market's robust growth trajectory and innovation in therapies beyond diabetes management.
AstraZeneca PLC stock (US6549022043): analysts update views as pipeline news keeps investors alert
AstraZeneca PLC (US6549022043) remains a focus for investors in May 2026 due to updated analyst commentary and new pipeline developments, particularly in its respiratory portfolio. Analysts see a moderate upside potential for the stock, with an average 12-month price target of USD 205.33, implying differing views on the company's future growth trajectory. The company’s pipeline success, especially in biologics for respiratory conditions, along with its strong presence in oncology and cardiovascular treatments, are key drivers for its valuation and long-term earnings profile.
Eli Lilly Experimental Drug Shows Surgery-Level Weight Loss in Phase 3 Trial
Eli Lilly's experimental drug, retatrutide, has demonstrated unprecedented weight loss in Phase 3 clinical trials, achieving an average reduction of 28% over 18 months, which is comparable to bariatric surgery outcomes. This "triple agonist" targets three hormone receptors (GLP-1, GIP, and glucagon), distinguishing it from current GLP-1 therapies. While the drug shows significant promise in treating obesity and related comorbidities, regulatory approval will depend on a thorough review of its safety profile and long-term data.
BioNTech SE stock (US09075V1026): focus shifts from COVID boom to oncology pipeline and new data cat
BioNTech SE is transitioning its focus from its COVID-19 vaccine success back to its oncology pipeline, with recent governance changes and clinical updates highlighting this strategic shift. The company is deploying its COVID-19 related financial resources into expanding its clinical pipeline, manufacturing capabilities, and digital initiatives for individualized cancer vaccines. For U.S. investors, the stock's performance is increasingly influenced by trial readouts, regulatory milestones, and evolving revenue guidance from its oncology programs.
Genmab A/S stock (DK0010272202): cancer drug specialist updates outlook after recent earnings
Genmab A/S has updated its financial guidance after releasing its latest quarterly results, with focus remaining on its oncology partnerships. The company's revenue growth is driven by key oncology antibodies like Darzalex and Tivdak, counterbalanced by increased R&D spending as it invests in new platforms and clinical programs. Genmab emphasizes its dual listing on Nasdaq and its exposure to the U.S. oncology market, making it noteworthy for US-based investors.
Is Vaccine And Hematology Progress Reshaping The Investment Case For Pfizer (PFE)?
Pfizer recently announced strong Phase 2 data for its 25-valent pneumococcal vaccine in infants and secured European approval for HYMPAVZI's expanded use in hemophilia patients. These developments enhance Pfizer's position in complex vaccines and rare hematology, aligning with its strategy to offset patent expirations and pricing pressures through targeted innovation. Investors are encouraged to consider these pipeline successes against ongoing challenges like patent Cliffs and drug price reforms affecting future earnings and dividend stability.
Truist Financial Corporation $TFC Shares Sold by HighTower Advisors LLC
HighTower Advisors LLC reduced its stake in Truist Financial Corporation (NYSE:TFC) by 4.1% in the fourth quarter, selling 49,356 shares. Despite this sale, Truist Financial reported strong quarterly results, beating EPS and revenue estimates, and announced a quarterly dividend of $0.52 per share. The stock currently holds a "Moderate Buy" rating from analysts with an average price target of $55.59.
Inmune Bio Inc stock (US45764T1060): eyes on upcoming 2025 results and Alzheimer’s pipeline
Inmune Bio Inc (INMB) is preparing to release its full-year 2025 financial results and provide a corporate update on March 30, 2026. The clinical-stage biotechnology company focuses on developing therapies for neuroinflammatory and oncological diseases, with a significant pipeline in Alzheimer's disease. Investors are closely watching for updates on cash runway, strategic priorities, and clinical milestones, given the company's reliance on capital markets and the early stage of its drug development.
Sarah Cannon Research Institute Announces Strategic Oncology Research Collaboration with Pfizer
Sarah Cannon Research Institute (SCRI) has announced a strategic oncology research collaboration with Pfizer Inc. to accelerate the development of Pfizer's oncology portfolio. This partnership will leverage SCRI’s Accelero™ model, a next-generation clinical trial delivery system, to streamline operations, enhance efficiency, and expand patient access to innovative therapies in community settings. The collaboration aims to bring promising therapies to patients faster and closer to home by combining Pfizer's innovation with SCRI's integrated research infrastructure and broad U.S. patient access.
Dr. Reddy's Laboratories Ltd stock (INE089A01023): recent price action and business overview
Dr. Reddy's Laboratories Ltd shares have recently traded around the ₹1,320 mark on Indian exchanges, reflecting a period of relatively stable activity after a 5-for-1 stock split in late 2024. The company, a prominent global player in generics and specialty pharmaceuticals, generates revenue from generic formulations, active pharmaceutical ingredients, biosimilars, and specialty products across markets like the U.S., India, and Europe. For U.S. investors, Dr. Reddy's offers diversified exposure to the Indian pharmaceutical sector through ADRs, influenced by both international healthcare trends and U.S. regulatory and pricing dynamics.
Moderna, Inc. Trade Ideas — LSX:A2N9D9
The article compiles various trade ideas and technical analyses for Moderna, Inc. (LSX:A2N9D9) from multiple traders. Discussions cover both bullish and bearish perspectives, analyzing price movements, RSI levels, potential breakouts, and corrections, often linking share performance to news like vaccine pricing and FDA designations.
AstraZeneca plc stock (GB0009895292): Latest catalyst after recent company news
AstraZeneca plc (GB0009895292) remains a key focus for investors, particularly those in the U.S. seeking global pharmaceutical exposure. The company's performance is driven by its strong portfolio in oncology, cardiovascular, respiratory, and rare diseases, with investor attention centered on clinical trial data, regulatory approvals, and pipeline updates. The article emphasizes AstraZeneca's significance as a bellwether for the broader pharma industry and its potential as a defensive investment during economic uncertainty.
Pfizer Inc. Financial Statements – BVL:PFEUS
This page provides financial data for Pfizer Inc. (PFEUS) on the Lima Stock Exchange, indicating it is a research-based global biopharmaceutical company founded in 1849. However, it notes that key financial figures such as market capitalization, revenue, and net income data are currently unavailable, and the company has never paid dividends.
Equity in earnings of Pfizer Inc. – BVL:PFEUS
The article provides a financial overview of Pfizer Inc. (PFEUS) on the Lima Stock Exchange, specifically focusing on "Equity in earnings." It highlights that the market was closed with no trades recorded at the time of the report. The content also lists various data providers for market and reference data, including ICE Data Services and FactSet.
Pfizer Inc. Income Statement – BVL:PFEUS
This article provides an income statement overview for Pfizer Inc. (BVL:PFEUS) on the Lima Stock Exchange. It highlights that the total revenue for the last quarter was 50.58 billion PEN, marking a 14.39% decrease from the previous quarter, with a net income of 9.41 billion PEN for Q1 2026. The page also presents a detailed, though currently unaudited and incomplete, breakdown of income statement line items across several years.
Pfizer Inc. Statistics – BVL:PFEUS
This article provides key financial statistics and ratios for Pfizer Inc. (BVL:PFEUS) on the Lima Stock Exchange. It highlights the company's price-to-sales ratio, enterprise value to EBITDA ratio, and employee count as of 2025. The content also presents a detailed, but mostly unpopulated, table for annual and quarterly metrics across various financial categories from 2006 to 2025.
Free float of Pfizer Inc. – BVL:PFEUS
This article provides details on the free float of Pfizer Inc. (PFEUS) on the Lima Stock Exchange, accessible through TradingView. It indicates that the market was closed with no trades at the time of publication and lists source data providers for market and reference data.
Pfizer Moves Next-Gen Vaccine Into Phase III In Prevnar Lifecycle Strategy
Pfizer has advanced its 25-valent pneumococcal vaccine into Phase III clinical trials, following positive Phase II data. This move is part of Pfizer's strategy to extend the lifecycle of its Prevnar franchise. The announcement was made on May 20, 2026 by Scrip.
HCW Biologics Jumps, Doubles Again as Traders Pile Into Biotech Name
HCW Biologics Inc. shares surged over 100% due to new securities filings, an ongoing Nasdaq listing dispute, and strong first-quarter results. The company is seeking to raise up to $5.6 million through stock or warrants to fund preclinical and clinical work, while also addressing a Nasdaq minimum bid price issue. Despite the rally, HCW faces risks including cumulative net losses and the need to secure financing and positive human data for its drug candidates.
Pfizer Builds Oncology Growth Around Padcev and Pipeline Expansion
Pfizer is focusing on its oncology segment for growth, driven by key therapies like Padcev and an expanding pipeline. Oncology sales accounted for 27% of total revenues and grew 7% in Q1 2026, with Padcev showing significant strength and receiving recent FDA approval for metastatic urothelial cancer in combination with Keytruda. The company plans to further expand Padcev's indications, develop new cancer treatments, and leverage its oncology biosimilars, despite competition from other major players like AstraZeneca, Merck, and J&J.
High Yield Healthcare Stocks: Why Pfizer, AbbVie, and Medtronic Are Worth Watching in 2026
This article examines three high-yield healthcare stocks—Pfizer, AbbVie, and Medtronic—detailing their unique dividend profiles and business models for income investors looking at 2026. Pfizer offers the highest yield with business challenges, AbbVie presents a balanced growth story with new drug successes, and Medtronic stands out for its consistent dividend history as a medical technology company. Each company provides a different risk-reward proposition driven by factors such as patent expirations, new drug pipelines, and market stability.
Pfizer Builds Oncology Growth Around Padcev and Pipeline Expansion
Pfizer is focusing on oncology for growth, with oncology
Pfizer Expands Pneumococcal Vaccine Push With New Programs
Pfizer announced positive Phase 2 data for its 25-valent pneumococcal conjugate vaccine candidate (25vPnC), showing strong immune responses in infants against key serotypes like serotype 3, leading to the initiation of a pediatric Phase 3 program. The company also plans to advance to a 35-valent candidate for adults, aiming to enter clinical development by the end of 2026. Pfizer's stock (PFE) saw a slight increase in premarket trading following the news.
Keysight Technologies Q2 2026: $2B in Orders and 69% EPS Growth, Is the Stock Already Priced for It at $344?
Keysight Technologies (KEYS) reported a record-breaking Q2 FY2026 with $1.717B in revenue, up 31% YoY, and adjusted EPS of $2.87, up 69% YoY, driven by strong growth in Communications Solutions and Electronic Industrial Solutions Groups. Orders surpassed $2 billion for the first time, propelled by AI-related business, and the company raised its full-year guidance. Despite the robust performance, TIKR's valuation model suggests the stock, currently trading at $344, is priced for a high-case scenario, implying a negative annualized return in the mid-case over the next 4.5 years.
Immunovant (NASDAQ: IMVT) shifts to IMVT-1402 with broad late-stage autoimmune program
Immunovant (NASDAQ: IMVT) is re-focusing its entire pipeline on IMVT-1402, a next-generation antibody, due to its positive Phase 1 data showing deep IgG reductions without significant off-target effects. This shift follows the discontinuation of batoclimab after its Phase 3 trials for Thyroid Eye Disease failed to meet primary endpoints. Immunovant plans to advance IMVT-1402 through late-stage clinical trials across six autoimmune indications, including Graves’ disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, Sjögren’s disease, and cutaneous lupus erythematosus, leveraging prior clinical learnings and aiming for a best-in-class profile with subcutaneous self-administration.
Pfizer begins late-stage trial for new pneumococcal shot in infants after strong Phase 2 data
Pfizer has initiated a Phase 3 trial for its 25-valent pneumococcal vaccine, PF-07872412 (25vPnC), in infants. This decision follows strong mid-stage trial results where 25vPnC demonstrated superior performance compared to its existing pneumococcal 20-valent conjugate vaccine, Prevnar 20. The late-stage trial aims to further evaluate the efficacy and safety of the new vaccine in an infant population.
Pfizer Stock Shares $49 Bil Success With Investors
Pfizer (PFE) has returned $49 billion to shareholders over the last five years through dividends and buybacks, making it the 30th highest in history for shareholder returns. This strategy, though attractive for direct returns, prompts questions about sacrificing growth, especially given Pfizer's recent revenue shocks and slower growth compared to companies like Meta and Microsoft. The article emphasizes the importance of staying invested and suggests a diversified portfolio approach to manage risk and secure returns.
AbbVie stock (US00287Y1091): investors eye Skyrizi and Rinvoq momentum after latest quarterly update
AbbVie's latest quarterly results show a continued transition away from its former blockbuster drug Humira, with significant growth from immunology drugs Skyrizi and Rinvoq, as well as contributions from aesthetics and neuroscience segments. While Humira sales decline, the company's diversified portfolio aims to reshape its earnings profile. Investors are watching its performance amidst regulatory developments and competitive pressures in the pharmaceutical industry.
Sanofi S.A. stock (FR0000120578): diabetes and immunology pipeline in focus after recent updates
Sanofi S.A. has recently shared updates on its diabetes and immunology pipeline, including its blockbuster drug Dupixent and new once-weekly insulin candidates, as it shifts its strategic focus towards higher-growth specialty care drugs and vaccines. The company's performance will depend on its R&D strategy, competitive landscape, and regulatory developments, particularly in the US market, which is a significant revenue driver. Sanofi offers US investors exposure to a diversified pharmaceutical portfolio via its American Depositary Receipts.
Vistra Q1 2026 Earnings Beat Hides a Bigger Story: The Power Demand Case Has Not Been Priced In
Vistra Corp. (VST) reported a record Q1 2026 profit, with adjusted EBITDA up 20% year-over-year, driven by increased power demand and higher energy prices. Despite the strong earnings and positive analyst outlook, Vistra's stock is down year-to-date and trades near a 52-week low. Analysts believe the stock is undervalued, as the market has not fully priced in the long-term structural electricity demand growth projected by management, particularly from data centers and electrification.
Pfizer Stock at $25: A $29 Wall Street Mean Target Backed by Two Legal Wins and 22% Portfolio Growth
Pfizer (PFE) reported a strong Q1 2026 revenue beat, driven by demand for Eliquis and 22% operational growth from new products. The company also secured crucial legal wins, including extending Vyndamax patent protection to 2031 and favorable COVID-vaccine contract rulings, which de-risk future earnings. Despite ongoing pressures from patent expirations and declining COVID-related sales, Wall Street maintains a mean target of $29, suggesting undervaluation on a multi-year basis with potential for re-rating based on pipeline execution.
Universal Technical Institute Stock To $25?
Universal Technical Institute (UTI) stock has recently dropped by 13.1% in less than a month, from $41.50 to $36.08. Trefis maintains an "Unattractive" opinion on the stock and suggests it could fall further, possibly to $25, citing historical price levels and the potential for a deeper correction. Although historical data shows a median 12-month return of 8.2% after sharp dips, investors are advised against timing the bottom and instead to consider strategies like the Trefis High Quality Portfolio for consistent returns.
Pfizer's pneumococcal shot shows stronger immune response in mid-stage trial
Pfizer announced that its experimental 25-valent pneumococcal vaccine (25vPnC) demonstrated a significantly stronger immune response in a mid-stage trial compared to its current Prevnar 20 shot. The new vaccine generated up to 15-fold higher antibody levels against a key strain and was well tolerated without safety concerns. Pfizer has now initiated a late-stage trial for 25vPnC in infants and plans to begin clinical development for an adult pneumococcal vaccine targeting 35 strains by the end of 2026.
Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Positive Phase 2 Results
Pfizer announced strong positive Phase 2 results for its investigational 25-valent pneumococcal conjugate vaccine (25vPnC) in infants, demonstrating robust immunogenicity and expanded protection across 25 serotypes, including significantly enhanced responses against serotype 3. This vaccine aims to cover up to 90% of disease-causing serotypes in young children, leading Pfizer to initiate its pivotal Phase 3 pediatric program. Additionally, Pfizer is advancing an adult 35-valent vaccine candidate to further strengthen its pneumococcal vaccine leadership.
